On March 2, 2022, Canexia Health Inc. (“Canexia”), an innovator in genomics-based cancer testing, completed its merger with Imagia Cybernetics Inc. (“Imagia”), a Montréal-based AI-healthcare company. Implemented through a statutory plan of arrangement under the Business Corporations Act (British Columbia), a newly formed private company – Imagia Canexia Health Inc. (“ICH”) – acquired all of Canexia and Imagia’s outstanding securities. The merger included a $20 million funding with participation from BDC Capital’s Women in Technology Venture Fund, Desjardins Capital, and PacBridge Capital.
ICH will improve access to precise, affordable cancer tests and treatments by combining Canexia’s advanced molecular cancer solutions with Imagia’s healthcare and AI expertise.
Farris LLP represented Canexia with a team led by R. Hector MacKay-Dunn, Q.C., and which included Teresa Tomchak (Litigation); Marylee A. Davies (Employment); Daniel Everall and Michael Rawluk (Corporate/M&A); and Ronald A. Chin (Intellectual Property).